-DOCSTART- -X- O
OBJECTIVE -X- _ O
: -X- _ O
Bronchiolitis -X- _ O
, -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
common -X- _ O
reasons -X- _ O
for -X- _ O
hospitalisation -X- _ O
in -X- _ O
young -X- _ O
children -X- _ O
, -X- _ O
is -X- _ O
particularly -X- _ O
problematic -X- _ O
in -X- _ O
Indigenous -X- _ O
children. -X- _ O
Macrolides -X- _ O
may -X- _ O
be -X- _ O
beneficial -X- _ O
in -X- _ O
settings -X- _ O
where -X- _ O
children -X- _ O
have -X- _ O
high -X- _ O
rates -X- _ O
of -X- _ O
nasopharyngeal -X- _ O
bacterial -X- _ O
carriage -X- _ O
and -X- _ O
frequent -X- _ O
prolonged -X- _ O
illness. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
our -X- _ O
double-blind -X- _ O
placebo-controlled -X- _ O
randomised -X- _ O
trial -X- _ O
was -X- _ O
to -X- _ O
determine -X- _ O
if -X- _ O
a -X- _ O
large -X- _ B-Intervention
single -X- _ I-Intervention
dose -X- _ I-Intervention
of -X- _ I-Intervention
azithromycin -X- _ I-Intervention
( -X- _ O
compared -X- _ O
to -X- _ O
placebo -X- _ B-Comparison
) -X- _ O
reduced -X- _ O
length -X- _ O
of -X- _ O
stay -X- _ O
( -X- _ O
LOS -X- _ O
) -X- _ O
, -X- _ O
duration -X- _ O
of -X- _ O
oxygen -X- _ O
( -X- _ O
O -X- _ O
( -X- _ O
2 -X- _ O
) -X- _ O
) -X- _ O
and -X- _ O
respiratory -X- _ O
readmissions -X- _ O
within -X- _ O
6 -X- _ O
months -X- _ O
of -X- _ O
children -X- _ B-Comparison
hospitalised -X- _ I-Comparison
with -X- _ I-Comparison
bronchiolitis. -X- _ I-Comparison
We -X- _ O
also -X- _ O
determined -X- _ O
the -X- _ O
effect -X- _ B-Intervention
of -X- _ I-Intervention
azithromycin -X- _ I-Intervention
on -X- _ O
nasopharyngeal -X- _ O
microbiology. -X- _ O
METHODS -X- _ O
: -X- _ O
Children -X- _ B-Patient
aged -X- _ I-Patient
â‰¤18 -X- _ I-Patient
months -X- _ I-Patient
were -X- _ O
randomised -X- _ O
to -X- _ O
receive -X- _ O
a -X- _ O
single -X- _ B-Intervention
large -X- _ I-Intervention
dose -X- _ I-Intervention
( -X- _ I-Intervention
30 -X- _ I-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
either -X- _ I-Intervention
azithromycin -X- _ I-Intervention
or -X- _ O
placebo -X- _ B-Comparison
within -X- _ O
24 -X- _ O
hrs -X- _ O
of -X- _ O
hospitalisation. -X- _ O
Nasopharyngeal -X- _ O
swabs -X- _ O
were -X- _ O
collected -X- _ O
at -X- _ O
baseline -X- _ O
and -X- _ O
48hrs -X- _ O
later. -X- _ O
Primary -X- _ O
endpoints -X- _ O
( -X- _ O
LOS -X- _ O
, -X- _ O
O -X- _ O
( -X- _ O
2 -X- _ O
) -X- _ O
) -X- _ O
were -X- _ O
monitored -X- _ O
every -X- _ O
12 -X- _ O
hrs. -X- _ O
Hospitalised -X- _ O
respiratory -X- _ O
readmissions -X- _ O
6-months -X- _ O
post -X- _ O
discharge -X- _ O
was -X- _ O
collected. -X- _ O
RESULTS -X- _ O
: -X- _ O
97 -X- _ O
children -X- _ O
were -X- _ O
randomised -X- _ O
( -X- _ O
n -X- _ B-Intervention
= -X- _ I-Intervention
50 -X- _ I-Intervention
azithromycin -X- _ I-Intervention
, -X- _ O
n -X- _ B-Comparison
= -X- _ I-Comparison
47 -X- _ I-Comparison
placebo -X- _ I-Comparison
) -X- _ O
. -X- _ O
Median -X- _ B-Outcome
LOS -X- _ I-Outcome
was -X- _ I-Outcome
similar -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
groups -X- _ I-Outcome
; -X- _ I-Outcome
azithromycin -X- _ I-Outcome
= -X- _ I-Outcome
54 -X- _ I-Outcome
hours -X- _ I-Outcome
, -X- _ I-Outcome
placebo -X- _ I-Outcome
= -X- _ I-Outcome
58 -X- _ I-Outcome
hours -X- _ I-Outcome
( -X- _ I-Outcome
difference -X- _ I-Outcome
between -X- _ I-Outcome
groups -X- _ I-Outcome
of -X- _ I-Outcome
4 -X- _ I-Outcome
hours -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
-8 -X- _ I-Outcome
, -X- _ I-Outcome
13 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.6 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
O -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
) -X- _ I-Outcome
requirement -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
different -X- _ I-Outcome
between -X- _ I-Outcome
groups -X- _ I-Outcome
; -X- _ I-Outcome
Azithromycin -X- _ I-Outcome
= -X- _ I-Outcome
35 -X- _ I-Outcome
hrs -X- _ I-Outcome
; -X- _ I-Outcome
placebo -X- _ I-Outcome
= -X- _ I-Outcome
42 -X- _ I-Outcome
hrs -X- _ I-Outcome
( -X- _ I-Outcome
difference -X- _ I-Outcome
7 -X- _ I-Outcome
hours -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
-9 -X- _ I-Outcome
, -X- _ I-Outcome
13 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.7 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Number -X- _ I-Outcome
of -X- _ I-Outcome
children -X- _ I-Outcome
re-hospitalised -X- _ I-Outcome
was -X- _ I-Outcome
similar -X- _ I-Outcome
10 -X- _ I-Outcome
per -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
= -X- _ I-Outcome
0.9 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
0.3 -X- _ I-Outcome
, -X- _ I-Outcome
2 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.8 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
At -X- _ I-Outcome
least -X- _ I-Outcome
one -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
74 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
children. -X- _ I-Outcome
The -X- _ I-Outcome
azithromycin -X- _ I-Outcome
group -X- _ I-Outcome
had -X- _ I-Outcome
reduced -X- _ I-Outcome
nasopharyngeal -X- _ I-Outcome
bacterial -X- _ I-Outcome
carriage -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
but -X- _ I-Outcome
no -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
detection -X- _ I-Outcome
at -X- _ I-Outcome
48 -X- _ I-Outcome
hours. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Although -X- _ B-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
azithromycin -X- _ I-Outcome
reduces -X- _ I-Outcome
carriage -X- _ I-Outcome
of -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
it -X- _ I-Outcome
is -X- _ I-Outcome
unlikely -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
beneficial -X- _ I-Outcome
in -X- _ I-Outcome
reducing -X- _ I-Outcome
LOS -X- _ I-Outcome
, -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
O -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
) -X- _ I-Outcome
requirement -X- _ I-Outcome
or -X- _ I-Outcome
readmissions -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
hospitalised -X- _ I-Outcome
with -X- _ I-Outcome
bronchiolitis. -X- _ I-Outcome
It -X- _ I-Outcome
remains -X- _ I-Outcome
uncertain -X- _ I-Outcome
if -X- _ I-Outcome
an -X- _ I-Outcome
earlier -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
azithromycin -X- _ I-Outcome
improves -X- _ I-Outcome
clinical -X- _ I-Outcome
and -X- _ I-Outcome
microbiological -X- _ I-Outcome
outcomes -X- _ I-Outcome
for -X- _ I-Outcome
children. -X- _ I-Outcome
The -X- _ O
trial -X- _ O
was -X- _ O
registered -X- _ O
with -X- _ O
the -X- _ O
Australian -X- _ O
and -X- _ O
New -X- _ O
Zealand -X- _ O
Clinical -X- _ O
Trials -X- _ O
Register. -X- _ O
Clinical -X- _ O
trials -X- _ O
number -X- _ O
: -X- _ O
ACTRN12608000150347. -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
www.anzctr.org.au -X- _ O
/ -X- _ O
TrialSearch.aspx -X- _ O
. -X- _ O

